

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 6 : <b>A61K 9/20</b></p>		<p>(11) International Publication Number: <b>WO 97/38679</b></p>
		<p>(43) International Publication Date: <b>23 October 1997 (23.10.97)</b></p>
<p>(21) International Application Number: <b>PCT/EP97/01696</b></p>		<p>(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p>
<p>(22) International Filing Date: <b>4 April 1997 (04.04.97)</b></p>		<p><b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(30) Priority Data: 96810236.8 <b>16 April 1996 (16.04.96)</b> EP (34) Countries for which the regional or international application was filed: <b>DE et al.</b></p>		
<p>(71) Applicant (for all designated States except US): <b>NOVARTIS CONSUMER HEALTH S.A. [CH/CH]</b>; Route de l'Etraz, CH-1260 Nyon (CH).</p>		
<p>(72) Inventors; and (75) Inventors/Applicants (for US only): <b>HUMBERT-DROZ, Pierre [CH/CH]</b>; 201, route de Collex, CH-1239 Collex-Bossy (CH). <b>SEIDEL, Matthias [DE/CH]</b>; Chemin Crozet, CH-1260 Nyon (CH). <b>MARTANI, Rosa [FR/FR]</b>; 51, rue des Bains, F-01220 Divonne-les-Bains (FR).</p>		
<p>(74) Agent: <b>BECKER, Konrad; Novartis AG, Patent- und Markenabteilung, Klybeckstrasse 141, CH-4002 Basel (CH).</b></p>		
<p>(54) Title: <b>FAST DISINTEGRATING ORAL DOSAGE FORM</b></p>		
<p>(57) Abstract</p> <p>The invention relates to a solid pharmaceutical dosage form for oral administration, which disintegrates very rapidly when taken into the mouth. Moreover, the invention relates to an advantageous, non-expensive process for the manufacture of said solid oral pharmaceutical dosage forms.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TC	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

**FAST DISINTEGRATING ORAL DOSAGE FORM**

The present invention relates to the field of pharmaceutical orally ingested solid dosage forms, which are designed to dissolve rapidly within the mouth. Currently two main technologies are used to obtain such type of dosage forms: (1) The active ingredient is mixed with water-soluble diluents and compressed on a tabletting machine at low to medium compression force. This is the more conventional approach. (2) A suspension is prepared with the active ingredient and appropriate excipients. The suspension is dispensed into blister packs and freeze-dried.

Many people are unwilling and/or unable to swallow tablets, capsules or traditional solid dosage forms. One approach suitable for these persons is the use of effervescent tablets or granules. However, the use of effervescent tablets requires preparatory steps before administration of the drug and the presence of water and a suitable mixing container. In addition, the manufacture and stability of effervescent tablets is often problematic. Another possibility is the use of a chewing gum or chewing tablet containing a medicament capable of absorption through the buccal cavity. Substantial disadvantages inherent in such a delivery system are that many medicaments are not suited for buccal absorption and that many persons are not able to chew gums or tablets because of braces, dental work etc. Furthermore, gums are often difficult to prepare.

A more recent approach is the OraSolv® technology of the company Cima. OraSolv® is an oral dosage form, which involves incorporating microencapsulated drug ingredients into a tablet that dissolves in the mouth without the need for chewing or water. The OraSolv® tablets are obtained by compression and packed into special peel-off blister packs because their mechanical resistance is insufficient in normal blister packs. The OraSolv® tablets normally need 15 to 60 seconds to dissolve in the mouth, which is longer than ideally aspired to in modern fast melting oral dosage forms. The same disadvantage of dissolving not rapidly enough in the mouth is common with many other approaches to fast melting oral dosage forms.

A fast dissolving (normally in 3 to 5 seconds) oral drug delivery system named Zydis® is known from the company R.P. Scherer. The principle of this technology consists in

preparing an aqueous suspension of the active ingredient and the excipients, which is dispensed into blister packs and the water removed by a freeze drying process. The final product is obtained by sealing the dried product in special peel-off blister packs - like Orasolv® due to lacking mechanical resistance in normal blister packs. A major disadvantage of this technology is the time-consuming and costly freeze-drying process. Furthermore, the effectiveness of a freeze-drying process always depends on the physico-chemical parameters of the active substances used. For certain active substances, especially such having a high solubility in water, it is therefore difficult or impossible to apply a freeze-drying process and consequently this technology. Finally, the development of units with high doses (up to 500 mg or even 1000 mg) of active ingredients and/or combinations of active ingredients is difficult or impossible, respectively with this technology.

The present invention addresses the needs mentioned above and the problems encountered with currently available technologies. The expensive freeze-drying process is avoided. The manufacture of the dosage form of the invention is simple and suitable for a broad range of active ingredients with different physico-chemical parameters, for high dose unit forms (up to e.g. 1000 mg, in particular 500 mg, of active substance) and also for combinations of active ingredients.

The present invention provides a solid pharmaceutical dosage form adapted for direct oral administration, i.e. for direct insertion into the mouth of a patient. This is particularly useful in administration of medicaments to individuals who cannot or will not chew, such as debilitated patients, patients who have difficulty swallowing solids and the elderly.

Therefore, the present invention relates to a solid pharmaceutical dosage form for oral administration, consisting essentially of

- (a) at least one active substance,
- (b) at least one filler,
- (c) at least one binding agent, and
- (d) optionally usual auxiliaries,

which dosage form disintegrates when taken into the mouth within 15 seconds, preferably within 10 seconds, and especially within 5 seconds.

More precisely, the solid pharmaceutical dosage form consists essentially of a mixture, especially a homogeneous mixture, of the components (a), (b), (c) and (d) mentioned above.

Active substances are especially pharmaceuticals but may be also, for example, vitamins, minerals or dietary supplements. Pharmaceuticals may include, without limitation, antacids, analgesics, anti-inflammatories, antibiotics, laxatives, anorexics, antiasthmatics, antidiuretics, antiflatulents, antimigraine agents, antispasmodics, sedatives, antihyperactives, tranquilizers, antihistamines, decongestants, betablockers, hormones and combinations thereof. Preferred active substances are analgesics and non-steroidal anti-inflammatory drugs, such as diclofenac, ketoprofen, ibuprofen, aspirin or paracetamol or a pharmaceutically acceptable salt thereof, and hormones, e.g. melatonin. Especially preferred is diclofenac which may be present either as free acid or as a pharmaceutically acceptable salt thereof, e.g. the potassium or sodium salt.

The filler can be chosen from those known in the art including mannitol, lactose, calcium phosphates, calcium sulphates, sucrose, glucose, fructose, sorbitol and xylitol. It has been found that a particularly advantageous filler is mannitol, because it is particularly useful in forming the low density matrix of the dosage form that disintegrates rapidly within the mouth. Furthermore, mannitol permits an easy drying process of the formulation after filling the suspension/solution into the blisters because of its non-hygroscopic character. The filler is usually present in an amount of at least 50 weight-%, preferably at least 60 weight-%, and especially at least 70 weight-% of the total dosage form.

The binding agent (or binder) is primarily used to give sufficient consistency to the formulation to avoid breaking of the article when removed from the blisters and during handling. Binding agents that can be used include polyethylene glycols, acacia, tragacanth, starch, cellulose materials, polyvinylpyrrolidones, alginic acid or a salt or an ester thereof, carrageenan gum, xanthan gum, gellan gum and the like. Also gelatin comes into consideration as a binder.

Preferred as binding agents are polyethylene glycols, carrageenan gum, xanthan gum, gellan gum, starch, cellulose materials, polyvinyl pyrrolidones, alginic acid or a salt or an ester thereof, and also gelatin.

Especially preferred are polyethylene glycols and polyvinylpyrrolidones. In particular, polyethylene glycol, e.g. polyethylene glycol 6000, is used. The binding agent is usually present in an amount of from 0.1 up to 10 weight-% and especially of from 0.2 up to 3 weight-% of the total dosage form.

Covered by the term "usual auxiliaries" are, for example, lubricants. They are primarily used to avoid sticking of the dried product to the surface of the mould. Examples of lubricants which can be used are talc, magnesium stearate or calcium stearate, stearic acid, polyethyleneglycols, sodium stearyl fumarate, hydrogenated vegetable oil, a behenic acid derivative and the like. It has been found that talc, hydrogenated vegetable oil and a behenic acid derivative - in particular talc - are especially useful lubricants in the dosage forms of the present invention. A behenic acid derivative is e.g. glyceryl behenate (also called "tribehenin") which corresponds to a mixture of glycerides (mainly triglycerides) of fatty acids (mainly behenic acid). Corresponding products on the market include the Compritol® series of the company Gattefossé (France). If used, the lubricant is usually present in an amount of up to 15 weight-%, e.g. in an amount of from 1 up to 15 weight %, and especially in an amount of up to 10 weight-% of the total dosage form.

The dosage forms of the present invention may include further auxiliaries (adjuvants) known in the art including flavors, aromas, sweeteners, colorants, buffering agents, acidifying agents, diluents, preservatives and the like.

The present invention further relates to a process for preparing the solid pharmaceutical dosage form for oral administration of the invention, which process comprises

- (A) preparing a suspension or solution which contains all the components (a), (b), (c) and (d) of the dosage form,
- (B) dispensing the suspension or solution into moulds, corresponding in size and shape to that of the pharmaceutical dosage form,
- (C) removing the solvent without applying a freeze-drying process, and
- (D) removing the dried units for storage in suitable containers or sealing them directly in the moulds.

Thus, the manufacture of the dosage form according to the present invention includes preparing a suspension (or solution), where the active ingredient is dispersed or dissolved in a solvent together with all the other components of the composition, such as fillers, binders and the usual auxiliaries present. The solvent is e.g. water, or a mixture of water with a co-solvent, e.g. ethanol, or even a pure non-aqueous solvent, e.g. ethanol. The active ingredient is normally used as the pure substance in different crystalline forms but it can also be e.g. microencapsulated. After preparation of the suspension (or solution), the latter is dispensed into moulds, e.g. blisters. This may be done either manually, semi-automatically or automatically.

Surprisingly, it is possible to dry the moulds, e.g. blisters, - that is to remove the solvent(s) - without applying a freeze-drying process, as known e.g. from the Zydis® technology of the prior art. This can be done, for example, by simple storage at room temperature or at elevated temperatures, or by storage at room temperature or at elevated temperatures under reduced pressure, or by applying microwave radiation, or by applying microwave radiation under reduced pressure. The evaporation normally is done at a temperature of from 10 up to 80°C, e.g. at room temperature between 15 and 25°C, or by heating up to 80°C, especially up to 50°C. "Under reduced pressure" preferably means pressures of from 0.1 mbar up to 200 mbar, but also high vacuum, e.g. 0.001 to 0.1 mbar, is possible. When microwave radiation is applied, this is preferably done in a system that is able to work on-line (continuously) during the manufacturing process. The process is simple and suitable for a broad range of active ingredients with different physico-chemical parameters, for high dose unit forms (up to 1000 mg, in particular 500 mg of active substance) and also for combinations of active ingredients.

From the above-said it has become clear that the dosage form of the present invention is manufactured without applying any compression force to the mixture of the components (a), (b), (c) and (d). As a result of the particular process of manufacture used, the dosage form of the invention normally has a density of 200-1000 mg/ml, preferably 300-900 mg/ml, more preferably 600-900 mg/ml, or 400-800 mg/ml. This is a density that is much lower than that of compressed dosage forms like normal tablets etc. (having densities of above 1000 mg/ml). As a result of its unusually low density, the dosage form of the invention

disintegrates more rapidly than would be the case, if the mixture of its components (a), (b), (c) and (d) are subjected to compression force.

The dried units may e.g. be sealed or removed from the moulds for storage in suitable containers. According to a preferred embodiment of the invention, the dried blisters are finally sealed to obtain the finished product, either in special peel-off blister packs or, preferably, in normal blister packs.

The dosage form is presented e.g. as a tablet of a size and shape adapted for direct oral administration to a patient. The tablet is pleasant to take and, once placed into the mouth, will disintegrate substantially and instantly without any voluntary action by the patient, e.g. chewing. Upon disintegration of the tablet, the active ingredient is released and can be swallowed as a suspension or absorbed from the buccal cavity. Buccal absorption can be particularly advantageous for substances submitted to a high first hepatic metabolism.

The dosage form according to the present invention is convenient to use for the consumer without the need of water or additional devices. Moreover, the instant disintegration and/or dissolution gives a sensation of a rapid and powerful action of the pharmaceutical dosage form and makes it unique and motivating for the patient to take.

An oral dosage form according to the present invention may also be, for example, a shaped article. The mass of each such an article is generally less than about 2.0 g. Preferably, the articles are circular, disk-like with a diameter between 5 and 20 mm.

The following examples illustrate the invention.

Example 1: Fast melting oral dosage form containing 12.5 mg of Diclofenac potassium (overall weight: 200 mg)

<u>Composition</u>	<u>mg/unit</u>
Diclofenac potassium	12.5
Mannitol	152.3
Polyethylene glycol 6000	1.6

Citric acid	10.0
Talc	16.0
Aspartam	6.0
Lemon aroma	1.6
Purified water	150.0

Diclofenac potassium, mannitol, talc, aspartam and the aroma are mixed for 5 min, sifted through a 0.5 mm mesh screen and then mixed again for 15 min. Citric acid and polyethylene glycol are dissolved in purified water. The former dry mixture containing diclofenac potassium etc. is suspended in the latter aqueous solution under stirring. While stirring, adequate aliquots of the suspension are dispensed manually with a pipette in blisters, and the blisters are dried at room temperature for 10 h. The dried units may now be removed from the blisters and stored in glass containers. Alternatively, the dried blisters may be sealed to obtain the finished product.

In an analogous manner as described in example 1, also the fast melting oral dosage forms of examples 2 to 5 are manufactured.

Example 2: Fast melting oral dosage form containing 12.5 mg of Diclofenac potassium  
(overall weight: 200,4 mg)

<u>Composition</u>	<u>mg/unit</u>
Diclofenac potassium	12.5
Mannitol	152.3
Polyvinylpyrrolidone	2.0
Citric acid	10.0
Talc	16.0
Aspartam	6.0
Lemon aroma	1.6
Purified water	150.0

Example 3: Fast melting oral dosage form containing 12.5 mg of Ketoprofen  
(overall weight: 190 mg)

<u>Composition</u>	<u>mg/unit</u>
Ketoprofen	12.5
Mannitol	152.3
Polyethylene glycol	1.6
Talc	16.0
Aspartam	6.0
Mint aroma	1.6
Purified water	150.0

Example 4: Fast melting oral dosage form containing 3.0 mg of Melatonin  
 (overall weight: 190 mg)

<u>Composition</u>	<u>mg/unit</u>
Melatonin	3.0
Mannitol	161.8
Polyethylene glycol	1.6
Talc	16.0
Aspartam	6.0
Mint aroma	1.6
Purified water	150.0

Example 5: Fast melting oral dosage form containing 12.5 mg diclofenac potassium  
 (overall weight : 400 mg)

<u>Composition</u>	(mg/unit)
Diclofenac potassium	12.5
Mannitol	353.5
Gellan gum	2
Polyethylene glycol	8
Talc	16
Aspartam	6
Mint aroma	2

- 9 -

Purified water	37.5
ethanol	75

In this example - contrary to example 1 - the drying of the blisters is done at 50°C under reduced pressure (0.1 mbar). Finally, the dried blisters are sealed to obtain the finished product.

Claims:

1. A solid pharmaceutical dosage form for oral administration, consisting essentially of

- (a) at least one active substance,
- (b) at least one filler,
- (c) at least one binding agent, and
- (d) optionally usual auxiliaries,

which dosage form disintegrates when taken into the mouth within 15 seconds.

2. A solid pharmaceutical dosage form for oral administration according to claim 1,

consisting essentially of

- (a) at least one active substance,
- (b) a filler,
- (c) a binding agent, and
- (d) optionally usual auxiliaries,

which dosage form disintegrates when taken into the mouth within 15 seconds.

3. A solid pharmaceutical dosage form for oral administration according to claim 1,

consisting essentially of a mixture of

- (a) at least one active substance,
- (b) at least one filler,
- (c) at least one binding agent, and
- (d) optionally usual auxiliaries,

which dosage form disintegrates when taken into the mouth within 15 seconds, and

which dosage form is manufactured without applying any compression force to the mixture of the components (a), (b), (c) and (d).

4. A solid pharmaceutical dosage form for oral administration according to claim 1,

consisting essentially of

- (a) at least one active substance,
- (b) at least one filler selected from the group consisting of mannitol, lactose, calcium phosphates, calcium sulphates, sucrose, glucose, fructose, sorbitol and xylitol,

- (c) at least one binding agent selected from the group consisting of polyethylene glycols, acacia, tragacanth, starch, cellulose materials, polyvinylpyrrolidones, alginic acid or a salt or an ester thereof, carrageenan gum, xanthan gum, gellan gum and gelatin, and
- (d) optionally usual auxiliaries.

5. A solid pharmaceutical dosage form for oral administration according to claim 1, consisting essentially of

- (a) at least one active substance,
- (b) at least one filler selected from the group consisting of mannitol, lactose, calcium phosphates, calcium sulphates, sucrose, glucose, fructose, sorbitol and xylitol,
- (c) at least one binding agent selected from the group consisting of polyethylene glycols, carrageenan gum, xanthan gum, gellan gum, starch, cellulose materials, polyvinyl pyrrolidones, alginic acid or a salt or an ester thereof, and gelatine, and
- (d) optionally usual auxiliaries.

6. A solid pharmaceutical dosage form for oral administration according to claim 1, consisting essentially of

- (a) at least one active substance,
- (b) a filler selected from the group consisting of mannitol, lactose, calcium phosphates, calcium sulphates, sucrose, glucose, fructose, sorbitol and xylitol,
- (c) a binding agent selected from the group consisting of polyethylene glycols, acacia, tragacanth, starch, cellulose materials, polyvinylpyrrolidones and alginic acids, and
- (d) optionally usual auxiliaries.

7. A solid pharmaceutical dosage form for oral administration according to claim 1, consisting essentially of

- (a) at least one active substance,
- (b) mannitol,
- (c) at least one binding agent selected from the group consisting of polyethylene glycols, polyvinylpyrrolidones, carrageenan gum, xanthan gum and gellan gum, and
- (d) optionally usual auxiliaries.

8. A solid pharmaceutical dosage form for oral administration according to claim 1, consisting essentially of

- (a) at least one active substance,
- (b) mannitol,
- (c) polyethylene glycol and gellan gum, and
- (d) optionally usual auxiliaries.

9. A solid pharmaceutical dosage form for oral administration according to any one of claims 1 to 8, wherein

the filler (b) is present in an amount of at least 50 weight-%, and

the binding agent(s) (c) is (are) present in an amount of from 0.1 up to 10 weight-% of the total dosage form.

10. A solid pharmaceutical dosage form for oral administration according to any one of claims 1-9, wherein the composition contains as usual auxiliaries (d) at least one lubricant and optionally other usual auxiliaries.

11. A solid pharmaceutical dosage form for oral administration according to claim 10, wherein the lubricant(s) used is (are) selected from the group consisting of talc, hydrogenated vegetable oil and a behenic acid derivative.

12. A solid pharmaceutical dosage form for oral administration according to claim 10, wherein the only lubricant used is talc.

13. A solid pharmaceutical dosage form for oral administration according to any one of claims 1 to 12, wherein the active substance is selected from diclofenac, ketoprofen, ibuprofen, aspirin, paracetamol, melatonin and pharmaceutically acceptable salts thereof.

14. A process for preparing a solid pharmaceutical dosage form for oral administration according to claim 1, which process comprises

- (A) preparing a suspension or solution which contains all the components (a), (b), (c) and (d) of the dosage form,
- (B) dispensing the suspension or solution into moulds, corresponding in size and shape to that of the pharmaceutical dosage form,

(C) removing the solvent without applying a freeze-drying process, and  
(D) removing the dried units for storage in suitable containers or sealing them directly in the moulds.

15. The process of claim 14, wherein step (C) is accomplished either by evaporating the solvent at a temperature of from 10 up to 80°C, optionally under reduced pressure, or by applying microwave radiation, optionally under reduced pressure.

16. The process of claim 14, in which the solvent used for the preparation of the suspension or solution under (A) is water, a mixture of water and ethanol, or ethanol.

17. The process of claim 14, in which the solvent used for the preparation of the suspension or solution under (A) is a mixture of water and ethanol.

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> <b>A61K 9/20</b>		<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 97/38679</b> <b>(43) International Publication Date:</b> <b>23 October 1997 (23.10.97)</b>
<b>(21) International Application Number:</b> <b>PCT/EP97/01696</b>		<b>(81) Designated States:</b> AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
<b>(22) International Filing Date:</b> <b>4 April 1997 (04.04.97)</b>		<b>(30) Priority Data:</b> 96810236.8 16 April 1996 (16.04.96) EP <i>(34) Countries for which the regional or international application was filed:</i> DE et al.	
<b>(71) Applicant (for all designated States except US):</b> NOVARTIS CONSUMER HEALTH S.A. [CH/CH]; Route de l'Etraz, CH-1260 Nyon (CH).		<b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HUMBERT-DROZ, Pierre [CH/CH]; 201, route de Collex, CH-1239 Collex-Bossy (CH). SEIDEL, Matthias [DE/CH]; Chemin Crozet, CH-1260 Nyon (CH). MARTANI, Rosa [FR/FR]; 51, rue des Bains, F-01220 Divonne-les-Bains (FR).		<b>(88) Date of publication of the international search report:</b> <b>4 December 1997 (04.12.97)</b>	
<b>(74) Agent:</b> BECKER, Konrad; Novartis AG, Patent- und Markenabteilung, Klybeckstrasse 141, CH-4002 Basel (CH).			

**(54) Title:** FAST DISINTEGRATING ORAL DOSAGE FORM**(57) Abstract**

The invention relates to a solid pharmaceutical dosage form for oral administration, which disintegrates very rapidly when taken into the mouth. Moreover, the invention relates to an advantageous, non-expensive process for the manufacture of said solid oral pharmaceutical dosage forms.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

Internat'l Application No  
PCT/EP 97/01696

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K9/20

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 651 997 A (YAMANOUCHI PHARMACEUTICAL CO. LTD.) 10 May 1995 see the whole document see page 8; example 2 ---	1-3, 9, 13-16 10-12
X	EP 0 627 218 A (NIPPON SHINYAKU COMPANY, LIMITED) 7 December 1994 see page 7; example 5 see page 9; table 1 ---	1, 2, 4-7, 9, 13
Y	US 5 330 760 A (WALTON) 19 July 1994 see column 4; claim 6 ---	10-12
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

1	Date of the actual completion of the international search  14 October 1997	Date of mailing of the international search report  28.10.97
	Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer  Benz, K

# INTERNATIONAL SEARCH REPORT

Intern	1st Application No
	PCT/EP 97/01696

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 34290 A (FUISZ TECHNOLOGIES LTD.) 21 December 1995 see the whole document see page 12, line 18 - line 25 see page 22, line 25 - line 29 see page 23, line 34 - page 24, line 1 ---	1,2, 4-10,13
X	WO 95 20953 A (THE BOOTS COMPANY PLC) 10 August 1995 see page 10 - page 11; example 1 ---	1,2
X	WO 95 20377 A (THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA ET AL.) 3 August 1995 see the whole document ---	1,2,4-7, 9
A		14-17
X	US 4 866 046 A (AMER) 12 September 1989 see column 5 - column 6; example 3 -----	1,2,4-6, 9,13

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Interr. Application No

PCT/EP 97/01696

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 651997 A	10-05-95	AU 3095992 A FI 943042 A NO 942403 A US 5466464 A CA 2126669 A HU 75455 A WO 9312769 A NZ 246091 A		28-07-93 23-06-94 24-08-94 14-11-95 08-07-93 28-05-97 08-07-93 28-08-95
EP 627218 A	07-12-94	CA 2130487 A DE 627218 T WO 9315724 A		19-08-93 24-08-95 19-08-93
US 5330760 A	19-07-94	AU 669918 B AU 4488393 A JP 6211672 A NZ 248515 A US 5543153 A		27-06-96 03-03-94 02-08-94 25-11-94 06-08-96
WO 9534290 A	21-12-95	AU 2767195 A EP 0762872 A NO 965387 A US 5616344 A US 5567439 A US 5653926 A US 5648033 A US 5662849 A US 5587172 A		05-01-96 19-03-97 13-02-97 01-04-97 22-10-96 05-08-97 15-07-97 02-09-97 24-12-96
WO 9520953 A	10-08-95	AU 1537095 A CA 2182038 A EP 0732920 A ZA 9500741 A		21-08-95 10-08-95 25-09-96 01-08-95
WO 9520377 A	03-08-95	US 5595761 A AU 680345 B AU 1688595 A BG 100749 A CN 1139877 A CZ 9602068 A		21-01-97 24-07-97 15-08-95 28-02-97 08-01-97 11-12-96

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat	Application No
	PCT/EP 97/01696

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9520377 A		EP 0743850 A FI 962989 A HU 74514 A NO 963140 A NZ 279674 A PL 315685 A SK 91096 A US 5587180 A ZA 9500677 A US 5635210 A	27-11-96 26-07-96 28-01-97 25-09-96 24-02-97 25-11-96 04-06-97 24-12-96 08-05-96 03-06-97
US 4866046 A	12-09-89	WO 9100096 A	10-01-91